Pharma Universalis
Turnover is estimated at about €120,000, probably between €97,000 and €170,000. The micro format does not state turnover.
Balance sheet
balance sheet total €129,198 on 31-12-2025in euro
in euro
Position in the sector
73.1%
Higher than 72% of the 10,299 companies filing micro accounts in office administrative support (NACE 82) in 2025.
3.64
Higher than 72% of the 9,879 companies filing micro accounts in office administrative support (NACE 82) in 2025.
35.5%
Higher than 80% of the 10,021 companies filing micro accounts in office administrative support (NACE 82) in 2025.
Net result: middle half · Equity: middle half · Balance sheet total: middle half · Working capital: middle half
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 |
|---|---|---|---|
| 59,622 | 57,214 | ||
| 47,254 | 45,685 | ||
| 94 | 6,693 | ||
| 58,918 | - | ||
| 90,109 | 42,910 | ||
| 73.1% | 68.1% | ||
| 3.64 | 2.95 | ||
| 0.37 | 0.47 | ||
| 48.5% | 89.7% | ||
| 35.5% | 61.1% | ||
| over 100 | over 100 |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 |
|---|---|---|---|
| Balance sheet: assets | |||
20/58 |
129,198 | 71,306 | |
20 |
0 | 94 | |
21/28 |
4,988 | 6,327 | |
22/27 |
4,988 | 6,327 | |
24 |
4,988 | 6,327 | |
29/58 |
124,209 | 64,886 | |
40/41 |
10,135 | 12,100 | |
40 |
10,135 | 12,100 | |
54/58 |
111,704 | 52,786 | |
490/1 |
2,370 | - | |
| Balance sheet: equity and liabilities | |||
10/49 |
129,198 | 71,306 | |
10/15 |
94,403 | 48,581 | |
10/11 |
5,000 | 5,000 | |
13 |
89,403 | 43,581 | |
133 |
89,403 | 43,581 | |
17/49 |
34,795 | 22,725 | |
42/48 |
34,100 | 21,976 | |
44 |
39 | 68 | |
440/4 |
39 | 68 | |
45 |
33,674 | 21,654 | |
450/3 |
30,594 | 18,590 | |
454/9 |
3,080 | 3,064 | |
47/48 |
386 | 254 | |
492/3 |
695 | 749 | |
| Income statement | |||
9900 |
59,622 | 57,319 | |
630 |
1,432 | 2,104 | |
640/8 |
0 | 106 | |
9901 |
58,190 | 55,110 | |
65/66B |
101 | 30 | |
65 |
101 | 30 | |
9903 |
58,088 | 55,080 | |
67/77 |
12,267 | 11,499 | |
9904 |
45,822 | 43,581 | |
9905 |
45,822 | 43,581 | |
| Appropriation of the result | |||
9906 |
45,822 | 43,581 | |
691/2 |
45,822 | 43,581 | |
6921 |
45,822 | 43,581 | |
| Document | |||
The full notes are in the filed accounts (PDF).
Source: Annual accounts 2025 (PDF), filed on 28-05-2026.
Filings
each dot is a set of accounts, on the day it reached the National BankInvestments
fixed assets acquired| Item | 2025 | 2024 |
|---|---|---|
| Tangible fixed assets | - | €6,693 |
| €1,432 | €2,104 |
Source: notes to the 2024 to 2025 annual accounts (statement of fixed assets)
Insights on Pharma Universalis
The operating result for 2025 is 6% higher than in 2024.
Debt's share of the balance-sheet total falls from 31.9% to 26.9%. Equity and debt are higher.